Compare Medtronic PLC (MDT) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs MasTec Inc — how do they compare? Medtronic PLC trades at $88.67 (market cap $112.24B), while MasTec Inc trades at $212.74 (market cap $17.40B). The key difference: Medtronic PLC is far larger — about 6.5× MasTec Inc's market cap, and Medtronic PLC pays a 3.28% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and MasTec Inc for 23 Days on average.
| MDT | MTZ | |
|---|---|---|
Market Cap | $112.24B | $17.40B |
Volume | 105,663,236 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $105.35 | $437.51 |
52-Week Low | $73.75 | $190.08 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | $131.58B | $20.32B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
MasTec (MTZ) trades at $214.84, down 3.82% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but a Q2 2026 miss, while fundamentals reveal solid revenue growth and profitability metrics. The company benefits from record backlog and infrastructure demand, particularly in power delivery and data center markets.
MTZ presents a compelling long-term opportunity with 89% analyst buy ratings and a $408.58 consensus target, though premium valuation and weak cash flow pose risks. Infrastructure spending tailwinds and AI-driven demand support growth, but execution challenges and communications segment softness require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
